EQS-News: MorphoSys' Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

EQS-News: MorphoSys AG / Key word(s): Conference MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in...

Related Keywords

California ,United States ,London ,City Of ,United Kingdom ,Massachusetts ,San Diego ,Boston ,Planegg ,Bayern ,Germany ,American ,Eamonn Nolan ,Raajitk Rampal ,Tim Demuth ,Thomas Biegi ,Julia Neugebauer ,Ruben Mesa ,Claire Harrison ,Memorial Sloan Kettering Cancer Center ,Drug Administration ,European Medicines Agency ,Exchange Commission ,Twitter ,Hilton San Diego Bayfront Hotel ,Nasdaq ,Myeloproliferative Neoplasms Program ,Lymphoma Society ,Linkedin ,Atrium Health Levine Cancer Center ,American Society Of Hematology ,Constellation Pharmaceuticals Inc ,Development Officer ,American Society ,Annual Meeting ,Hematologic Malignancies ,Memorial Sloan Kettering Cancer ,Spleen Size ,Professor Claire Harrison ,Bone Marrow ,Morphosys Chief Research ,Executive Director ,Morphosy Annual Report ,